Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Other Operating Expenses (2023 - 2025)

Historic Other Operating Expenses for Allogene Therapeutics (ALLO) over the last 3 years, with Q2 2025 value amounting to $2.4 million.

  • Allogene Therapeutics' Other Operating Expenses fell 5225.5% to $2.4 million in Q2 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 9177.54%. This contributed to the annual value of $15.7 million for FY2024, which is 1866.36% up from last year.
  • Allogene Therapeutics' Other Operating Expenses amounted to $2.4 million in Q2 2025, which was down 5225.5% from $10.7 million recorded in Q3 2024.
  • In the past 5 years, Allogene Therapeutics' Other Operating Expenses registered a high of $13.2 million during Q4 2023, and its lowest value of $2.4 million during Q2 2025.
  • Over the past 3 years, Allogene Therapeutics' median Other Operating Expenses value was $7.9 million (recorded in 2024), while the average stood at $7.8 million.
  • Over the last 5 years, Allogene Therapeutics' Other Operating Expenses had its largest YoY gain of 5225.5% in 2025, and its largest YoY loss of 5225.5% in 2025.
  • Quarter analysis of 3 years shows Allogene Therapeutics' Other Operating Expenses stood at $13.2 million in 2023, then fell by 19.0% to $10.7 million in 2024, then crashed by 77.8% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q2 2025, $10.7 million for Q3 2024, and $5.0 million during Q2 2024.